Taxotere® as second-line chemotherapy for metastatic breast cancer;Taxotere® en deuxieme ligne dans le cancer du sein metastatique

Revue de Medecine Interne

Volumn 20, Issue 3, 1999, Pages 277-280

  Culine, S ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Chemotherapy; Docetaxel; Metastatic breast cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ELLIPTINIUM ACETATE; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; THIOTEPA; VINDESINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS POTENTIAL; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; BREAST TUMOR; FEMALE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; TAXOIDS;

EID: 0344286544     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)83058-6     Document Type: Article

References (16)

1. Spielmann M. La chimiothérapie des cancers du sein métastatique. Namer M, Teissier E, Ferrero JM. Les traitements médicaux du cancer du sein. 1996;165-190 Arnette Blackwell, Paris.
2. Piccart MJ, Raymond E, Aapro M, Eisenhauer EA, Cvitkovic E. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer. 31A:1995;1-10. Suppl 7.
3. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Bhandari A, Valero V, et al. A unified definition of clinical anthracyline resistant breast cancer. [abstract] Proc Am Soc Clin Oncol. 16:1997;146a.
4. Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 14:1996;2197-2205.
5. Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracyline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 13:1995;2879-2885.
6. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 13:1995;2886-2894.
7. Guastalla JP, Bonneterre J, Fumoleau P, Piccart M, Tubiana M, Chevallier B, et al. A phase II trial of docetaxel in patients with anthacycline-resistant metastatic breast cancer. [abstract] Eur J Cancer. 31A:1995;75. Suppl 5.
8. Leonard RC, O'Brien M, Barrett-Lee P, Maling SJ, Eggleton SPH. 2 year outcome analysis of 377 pretreated advanced breast cancer patients treated with docetaxel in a community setting. [abstract] Proc Am Soc Clin Oncol. 17:1998;112a.
9. ® versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. [abstract] Proc Am Soc Clin Oncol. 16:1997;154a.
10. Sledge GW, Neuberg D, Ingle S, Martino S, Wood W. Phase III trial of doxorubicin vs paclitaxel vs doxorubicin + paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. [abstract] Proc Am Soc Clin Oncol. 16:1997;1a.
11. ® and doxorubicin as first- and second-line chemotherapy in advanced breast cancer. [abstract] Proc Am Soc Clin Oncol. 16:1997;154a.
12. ® versus mitomycin C + vinblastine in patients with metastatic breast cancer who have failed an anthracycline containing regimen: preliminary results of a randomized phase III study. [abstract] Proc Am Soc Clin Oncol. 16:1997;148a.
13. ® as second-line chemotherapy in patients with metastatic breast cancer (preliminary results). [abstract] Proc Am Soc Clin Oncol. 16:1997;162a.
14. Sjöström J, Mouridsen H, Pluzanska A, Ottoson Lönn S, Bengtsson NO, Ostenstad B, et al. Taxotere versus methotrexate-5-fluorouracil in patients with advanced anthracyclin-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group. [abstract] Proc Am Soc Clin Oncol. 17:1998;111a.
15. Dossier AMM, décembre 1996.
16. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol. 15:1997;3149-3155.